Synthesis and Antibacterial Activity of Novel 4″-O-(1-aralkyl-1,2,3-triazol-4-methyl-carbamoyl) Azithromycin Analogs.

Yinhu Wang,Chao Cong,Wern Chern Chai,Ruiqian Dong,Li Jia,Di Song,Ziteng Zhou,Shutao Ma

DOI: https://doi.org/10.1016/j.bmcl.2017.06.044

IF: 2.94

2017-01-01

Bioorganic & Medicinal Chemistry Letters

Abstract:Three novel structural series of 4 ''-O-(1-aralkyl-1,2,3-triazol-4-methyl-carbamoyl) azithromycin analogs were designed, synthesized and evaluated for their in vitro antibacterial activity. All the target compounds exhibited excellent activity against erythromycin-susceptible Streptococcus pyogenes, and significantly improved activity against three phenotypes of erythromycin-resistant Streptococcus pneumoniae compared with clarithromycin and azithromycin. Among the three series of azithromycin analogs, the novel series of 11,4 ''-disubstituted azithromycin analogs 9a-k exhibited the most effective and balanced activity against susceptible and resistant bacteria. Among them, compound 9j showed the most potent activity against Staphylococcus aureus ATCC25923 (0.008 Kg/mL) and Streptococcus pyogenes R2 (1 mu g/mL). Besides, all the 11,4 ''-disubstituted azithromycin analogs 9a-k except 9f shared the identical activity with the MIC value <0.002 mu g/mL against Streptococcus pyogenes S2. Furthermore, compounds 9g, 9h, 9j and 9k displayed significantly improved activity compared with the references against all the three phenotypes of resistant S. pneumoniae. Particularly, compound 9k was the most effective (0.06, 0.03 and 0.125 mu g/mL) against all the erythromycin-resistant S. pneumoniae expressing the erm gene, the mef gene and the erm and mef genes, exhibiting 2133, 133 and 2048-fold more potent activity than azithromycin, respectively. (C) 2017 Elsevier Ltd. All rights reserved.